Baird uses cookies to give you the best experience on our website. Some of these cookies are essential, while others help us to improve your experience. Please accept cookies to continue. By continuing to browse, you agree to the use of our cookies. For more detailed information on our use of cookies and our data privacy protections, please see our Cookie Policy or our European Client and Third Party Privacy Notice
Baird Capital has completed the sale of its equity interest in portfolio company PharMEDium through the close of a transaction with Clayton, Dubilier & Rice.
PharMEDium is a leading provider of outsourced pharmacy compounding services to the hospital market.